Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study

In this 96-week extension study (n=1,044) tezacaftor–ivacaftor was generally safe, well tolerated, and efficacious for up to 120 weeks; supporting the clinical benefit of long-term tezacaftor–ivacaftor treatment in these patients.

Source:

The Lancet Respiratory Medicine